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Objective: There has been growing interest in newer anti-epileptic drugs (AEDs) for seizure 
prophylaxis in the intensive care setting because of safety and monitoring issues associated 
with conventional AEDs like phenytoin. This analysis assessed the cost-effectiveness of leve-
tiracetam versus phenytoin for early onset seizure prophylaxis after neurosurgery and traumatic 
brain injury (TBI).
Methods: A cost-effectiveness analysis was conducted from the US hospital perspective using 
a decision analysis model. Probabilities of the model were taken from three studies comparing 
levetiracetam and phenytoin in post neurosurgery or TBI patients. The outcome measure was 
successful seizure prophylaxis regimen (SSPR) within 7 days, which was defined as patients 
who did not seize or require discontinuation of the AED due to adverse drug reactions (ADRs). 
One-way sensitivity analyses and probabilistic sensitivity analysis were conducted to test 
robustness of the base-case results.
Results: The total direct costs for seizure prophylaxis were $8,784.63 and $8,743.78 for 
levetiracetam and phenytoin, respectively. The cost-effectiveness ratio of levetiracetam was 
$10,044.91 per SSPR compared to $11,525.63 per SSPR with phenytoin. The effectiveness 
probability (patients with no seizures and no ADR requiring change in therapy) was higher in the 
levetiracetam group (87.5%) versus the phenytoin group (75.9%). The incremental cost effec-
tiveness ratio for levetiracetam versus phenytoin was $360.82 per additional SSPR gained.
Conclusions: Levetiracetam has the potential to be more cost-effective than phenytoin for 
early onset seizure prophylaxis after neurosurgery if the payer’s willingness-to-pay is greater 
than $360.82 per additional SSPR gained.
Keywords: phenytoin, levetiracetam, seizure prophylaxis, cost-effectiveness, traumatic brain 
injury (TBI), and neurosurgery
Introduction
Patient who undergo neurosurgery are at increased risk of early postoperative seizure 
events.1,2 An estimated 20% to 50% of patients have at least one postoperative seizure, 
depending on the type of surgery.3,4 Early postoperative seizures, which are seizures 
that occur within 1 week of surgery, occur in 15% to 20% of neurosurgery patients.3–5 
Patients who sustain traumatic brain injury (TBI) are also at increased risk, with 
about 6% to 10% of patients suffering early onset seizures.6,7 Incidence can be as 
high as 30% in certain groups, such as those with more severe head trauma, subdural 
hematomas, or penetrating head injuries.6–8 Seizure prophylaxis with antiepileptics ClinicoEconomics and Outcomes Research 2010:2 16
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has shown promise in reducing early onset seizures in both 
patient groups.2,9–11 However, there is no commonly accepted 
treatment algorithm to provide guidance as to which anti-
epileptic drug (AED) should be preferred which has led to a 
variety of clinical practices.12
Phenytoin is the most common AED used after neuro-
surgery and TBI for seizure prophylaxis.9–11,13 In a meta-
analysis that pooled early onset seizure events from five post 
neurosurgery trials, phenytoin was associated with decreased 
seizure risk in the first week by 44% (relative risk, RR: 
0.56, 95% confidence interval [CI]: 0.38–0.84) compared to 
control.13 Additionally, a review that pooled the two class I 
(randomized placebo controlled) studies investigating phe-
nytoin prophylaxis after TBI showed a 63% reduction in 
seizures (RR: 0.37, 95% CI: 0.18–0.74).9 Despite evidence 
that supports phenytoin use in early seizure prophylaxis, 
there are a number of issues that limit its use. Phenytoin 
requires constant laboratory monitoring which is a burden 
to the patient as well as time consuming for hospital staff.14 
Moreover, due to phenytoin’s zero-order (Michaelis-Menten) 
pharmacokinetics which result in a non-linear relationship 
between dose and subsequent serum levels, a small change 
in dose can result in a disproportionate increase in serum 
concentration.15 Furthermore, rare and potentially fatal skin 
reactions have been reported with phenytoin, such as Stevens 
Johnson syndrome and purple glove syndrome.16 Finally, 
phenytoin can act as a substrate or inducer of several of the 
cytochrome P450 enzyme which can potentially lead to drug 
interactions that may consequently require dose adjustments 
or discontinuation of medications.14
Due to these known problems with phenytoin for early 
seizure prophylaxis after neurosurgery, there has been an 
interest in using alternative AEDs for this indication. Other 
medications that have been evaluated for early onset seizure 
prophylaxis include carbamazepine, valproate, phenobarbital, 
and levetiracetam.9,17 Shaw et al evaluated cabamazepine 
(CBZ) against a no treatment historical cohort after neuro-
surgery and reported a 39% reduction in seizure events (RR: 
0.61, 95% CI: 0.29–1.29).4 Early onset seizure incidence was 
11% in the CBZ group (n = 106) and 19% in the no treatment 
historical cohort (n = 59).4 Glötzner et al in a prospective 
placebo-control study, assessed CBZ after TBI and reported 
a 63% reduction in early seizure events (RR: 0.37, 95% CI: 
0.18–0.78).18 Seizure incidence was 10.7% in the CBZ group 
(n = 75) and 28.9% (n = 76) in the placebo group.18 Holland 
et al, in a randomized double-blind study, evaluated valproate 
for seizure prophylaxis after craniotomy and reported a non-
significant 15% reduction (RR: 0.85, 95% CI: 0.54–1.36) in 
early and late seizures combined.19 Seizure event rates were 
17.8% for patients in the valproate group (n = 152) and 20.8% 
for patients in the control group (n = 149).19 Franceschetti et al 
reported that early seizures occurred in 7% of patients in a 
pooled phenytoin and phenobarbital group (n = 41) compared 
to 18% in the no treatment group (n = 22) after neurosurgery; 
however, this difference was not statistically significant.20
Unlike the other AEDs, levetiracetam offers several 
advantages for early onset seizure prophylaxis in neuro-
surgical or TBI patients. There are no required laboratory 
monitoring with levetiracetam; whereas, phenytoin requires 
plasma level and liver function tests. Levetiracetam has a 
wide therapeutic window and predictable pharmacokinetics 
which make dosing convenient. No severe or life threaten-
ing adverse drug reactions have been reported with leve-
tiracetam. In addition, there are very few known common 
drug interactions with levetiracetam. However, intravenous 
(iv) levetiracetam acquisition cost is much more expensive 
compared to phenytoin. Though prices will vary between 
different institutions and payers, the acquisition cost of iv 
levetiracetam is generally greater than the acquisition cost 
of iv phenytoin. Currently, there is no pharmacoeconomic 
analysis investigating early onset seizure prophylaxis with iv 
levetiracetam compared to iv phenytoin. To our knowledge, 
this was the first analysis to investigate the cost-effectiveness 
potential of levetiracetam versus phenytoin in postoperative 
early seizure prophylaxis.
Methods
Literature search strategy
A literature search was performed to identify clinical trials 
that investigated iv levetiracetam compared to iv phenytoin in 
post neurosurgical or TBI patients. Studies had to be a head-
to-head comparison between iv levetiracetam and iv phenytoin 
after neurosurgery or TBI. A total of 3 studies was identified 
and data were abstracted by two independent reviewers.21–23 
We focused on short-term seizure prophylaxis (within 7 days) 
and used the weighted mean average of seizure outcomes 
for our efficacy parameters in the decision analysis model. 
Probability parameters for ADR leading to discontinuation 
was taken from a single study.21 This study had the largest 
patient population and was the only study which clearly gave 
discontinuation rates secondary to ADRs.21
Decision analysis model
A cost-effectiveness analysis using a decision analysis 
model (Figure 1) was conducted from the United States 
(US) hospital perspective. The main outcome measure was ClinicoEconomics and Outcomes Research 2010:2 17
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a successful seizure prophylaxis regimen (SSPR). SSPR was 
defined as a patient receiving seizure prophylactic therapy 
that neither seized nor had an ADR resulting in a change 
in therapy. This outcome was justified by capturing seizure 
prevention as well ADR avoidance. Model parameters for 
efficacy outcomes were based on three published clinical 
trials (Table 1).21–23
Parameters for each branch of the decision analysis 
model included: 1) ADR probability requiring discontinua-
tion for each drug; and 2) seizure probabilities for the study 
drugs. The dosages and frequency for study drugs were 
assumed to be: iv levetiracetam 500 mg twice a day and iv 
phenytoin 100 mg 3 times a day. Patients who received iv 
phenytoin were also assumed to received a loading dose of 
fosphenytoin using 1500 mg (phenytoin equivalent) on day 
one of therapy.24
For parameters of the model that were not available in the 
literature, expert opinions were solicited. Two intensive care 
unit (ICU) pharmacists at our institution were interviewed 
and asked to answer questions on treatment probability. Based 
on expert opinions, an average ICU stay for neurosurgical 
patients was defined as 5 days. For patients who had an ADR 
requiring a change in therapy, it was assumed that their therapy 
adjustment was made 2 days postoperatively, which resulted in 
2 additional days in the ICU. Patients were then switched to a 
third agent (oral carbamazepine (CBZ) 200 mg 3 times a day), 
which was assumed to be effective. Moreover, patients were 
assumed to stay 5 additional days in the ICU after switching 
to CBZ. Carbamazepine was chosen as an appropriate agent 
to switch to after failure with either iv levetiracetam and iv 
phenytoin both by expert opinions and literature.4,9
It was assumed that seizure events would occur 2 days 
postoperatively, where their dose would be increased 
(iv levetiracetam to 1000 mg twice a day and iv phenytoin 
to 400 mg daily) and assumed to be effective.17 The patient 
was then assumed to stay 5 additional days in the ICU (per 
expert opinions). Based on expert opinions, it was estimated 
that patients having either a seizure or an ADR requiring a 
change in therapy will need 2 extra days in the ICU. Patients 
on iv phenytoin were assumed to have 3 phenytoin levels 
drawn if duration of therapy was 5 days or less or four lev-
els drawn if duration of therapy was more than 5 days (per 
expert opinions). All decision model inputs are provided 
in Table 2.
Breakdowns of each individual arm in the decision model 
are as follows:
a)  The patient receives levetiracetam iv 500 mg twice a day 
for 5 days and stays in the ICU for 5 days. The patient 
does not experience a seizure nor has an ADR requiring 
change in therapy.
b)  The patient receives levetiracetam iv 500 mg twice a day 
for 2 days and seizes. The dose is increased to 1000 mg 
twice a day for 5 days and is assumed to be successful. 
Patient spends a total of 7 days in the ICU.
Seizure prophylaxis in neurosurgical patients
Levetiracetam
No ADR
No Seizure
Seizure Increased dose
Increased dose
Switch to CBZ
No Seizure
Seizure
Switch to CBZ
ADR
No ADR
ADR
Phenytoin
Figure 1 Decision analysis model. square nodes indicate a decision is being made. Circle nodes indicate a chance probability. Triangles nodes represent terminal nodes.
Abbreviations: ADR, adverse drug reaction; CBZ, carbamazepine.
Table 1 studies (comparing levetiracetam vs phenytoin) utilized for model probabilities
Study n Study design Indication Outcome measure used Results
PHT LVT
Milligan21 315 RT neurosurgical sZ within 7 d of surgery 9/210 1/105
Jones22 73 PR (LVT), RT (PhT) TBi sZ within 7 d of trauma 0/41 1/32
Szaflarski23 52 PR, RCT TBi sZ within 4 d of trauma 3/18 5/34
Abbrevations: LVT, levetiracetam; PhT, phenytoin; d, days; PR, prospective; RCT, randomized control trial; RT, retrospective; TBi, traumatic brain injury.ClinicoEconomics and Outcomes Research 2010:2 18
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c)  The patient receives levetiracetam iv 500 mg twice a day 
for 2 days and has an ADR requiring change in therapy. 
The patient is then switched to CBZ iv 200 mg 3 times 
a day for 5 days and is assumed to be successful. Patient 
spends a total of 7 days in the ICU.
d)  The patient receives phenytoin iv 100 mg 3 times a day 
for 5 days and stays in the ICU for 5 days. The patient nei-
ther seizes, nor has an ADR requiring change in therapy. 
The patient was assumed to have three phenytoin levels 
drawn.
e)  The patient receives phenytoin iv 100 mg 3 times a day 
for 2 days and seizes. The dose is increased to a 400 mg 
total daily dose for 5 days and is assumed to be successful. 
Patient spends a total of 7 days in the ICU. The patient 
was assumed to have four phenytoin levels drawn.
f)  The patient receives phenytoin iv 100 mg 3 times a day 
for 2 days and has an ADR requiring change in therapy. 
The patient is then switched to CBZ iv 200 mg 3 times 
a day for 5 days, which is assumed to be successful. 
Patient spends a total of 7 days in the ICU. The patient 
was assumed to have three phenytoin levels drawn.
Economic analysis
This analysis was performed from the US hospital perspec-
tive ($US). As a result, only total direct costs were assessed. 
Drug acquisition costs were taken from the 2008 Red Book.25 
Hospital and laboratory costs were taken from the Veterans 
Affairs Decision Support Services (DSS) database (2008). 
DSS is the Veterans Affairs national database that provides 
costs for resource utilization directed at patient care. Dis-
counting was not taken into account due to the short duration 
of the DA model.
Primary endpoint was the incremental cost-effectiveness ratio 
(ICER), which was calculated using the following equation:26,27
ICER = Clevetiracetam – Cphenytoin/Elevetiracetam – Ephenytoin
where C is the total direct cost for the different treatment 
strategies and E is the probability of SSPR. Average cost-
effectiveness ratio (CER) was calculated for iv levetiracetam 
and iv phenytoin using the following equation:26,27
CER = C/E
where C is the total direct cost of using either iv levetiracetam 
or iv phenytoin and E is the probability of achieving SSPR 
with either iv levetiracetam or iv phenytoin.
sensitivity analysis
We evaluated the impact of parameter uncertainty by conduct-
ing one-way sensitivity analyses on all model parameters over 
the ranges listed in Table 2. A tornado diagram was used to 
illustrate the impact each of the one-way sensitivity analyses 
had on the incremental cost difference between iv leveti-
racetam and iv phenytoin. Probabilistic sensitivity analysis 
(second-order Monte Carlo simulation) was conducted using a 
cohort of 10,000 trial simulations. In probabilistic sensitivity 
analysis, each parameter of the model was given a reason-
able range with a distribution function which was randomly 
drawn using the stochastic process.26,28 Model probabilities 
were sampled using a beta distribution, and cost data were 
sampled using a gamma distribution.27 Resource utilization 
was sampled using a normal distribution. Random input values 
were then simulated through the model for a theoretical cohort 
of patients.26 Scatter plot distribution of ICER was plotted 
on a cost-effectiveness plane where the incremental cost is 
Table 2 Base-case parameters for the decision analysis model
Parameters Model input LL UL Reference
number of days sZ increases iCU stay 2 1 4 expert opinions
number of days ADR increases iCU stay 2 1 3 expert opinions
Average length of stay in iCU (days) 5 3 7 expert opinions, 21–23
Levetiracetam seizure probability 0.117 0 0.200 21–23
Levetiracetam ADR probability 0.01 0 0.050 21
Phenytoin seizure probability 0.074 0 0.200 21–23
Phenytoin ADR probability 0.181 0.081 0.281 21
Levetiracetam 500 mg vial cost ($Us) $46.40 $0.00 $150.00 25
Phenytoin 50 mg vial cost ($Us) $1.20 $0.00 $20.00 25
Carbamazepine 200 mg tablet cost ($Us) $0.94 $0.00 $5.00 25
iCU bed stay cost ($Us) $1,570.82 $500.00 $2,500.00 Dss data
Phenytoin lab cost ($Us) $3.73 $1.00 $7.00 Dss data
Abbreviations: ADR, adverse drug reaction; Dss, veterans affairs decision support services; iCU, intensive care unit; LL, lower limit; UL, upper limit; sZ, seizure.ClinicoEconomics and Outcomes Research 2010:2 19
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represented along the y-axis and the incremental efficacy is 
represented along the x-axis.29,30 A dominant strategy was 
defined as a strategy with lower incremental cost and higher 
incremental benefit. A cost-effectiveness acceptability curve 
(CEAC) was created in order to identify which treatment 
would be more cost-effective at various willingness-to-pay 
(WTP) thresholds (cost per additional SSPR gained).29,30 As 
WTP increases on the x-axis from left to right, the probability 
of iv levetiracetam being a cost-effective strategy compared to 
iv phenytoin may change based on the observed data. Analy-
sis was performed using TreeAge Pro Suite 2008 (TreeAge 
Software Inc., Williamstown, MA).
Results
In the base-case analysis, the total direct cost of iv levetiracetam 
and iv phenytoin were $8,784.63 and $8,742.78 per patient, 
respectively (Table 3). The cost-effectiveness ratios for iv 
levetiracetam and iv phenytoin were $10,044.91 per SSPR 
and $11,525.63 per SSPR, respectively. The ICER for using 
iv levetiracetam versus iv phenytoin was $360.82 per SSPR 
gained. The efficacy rate (patients with no seizures and no ADR 
requiring change in therapy) was higher in the iv levetiracetam 
Table 3 Base-case result of the decision analysis model
Intervention Total direct  
costs ($US)
Efficacy CER ICER
Levetiracetam $8,784.63 0.875 $10,044.91 $360.82
Phenytoin $8,742.78 0.759 $11,525.63 –
Abbreviations: CER, cost-effectiveness ratio; iCER, incremental cost-effectiveness 
ratio.
Levetiracetam 500 mg vial
Levetiracetam seizure probability
Phenytoin ADR probability
Phenytoin 50 mg vial
Number of days an ADR increases ICU stay (days)
Pheytoin seizure probability
ICU bed stay cost ($US)
Number of days a seizure increases ICU stay (days)
Levetiracetam ADR probability
Phenytoin lab cost ($US)
Carbamazepine 200 mg tablet
Average length of stay in ICU (days)
Incremental cost ($US)
−$600 −$400 −$200 $0 $200 $400 $600 $800 $1,000 $1,200 $1,400
Figure 2 Tornado diagram for one-way sensitivity analyses performed on the decision analysis model. The x-axis represents the incremental cost between intravenous (iv) 
levetiracetam and iv phenytoin. The parameters that were tested in the one-way sensitivity analyses are listed on the y-axis. Model parameters with the most influence on the 
base-case are listed at the top in descending order. The base-case incremental cost was $41.85. Any model parameter that crosses the threshold (incremental cost $0) creates 
a scenario where levetiracetam is dominant. White bars represent scenarios where decreasing the value of the parameter leads to iv levetiracetam being dominant compared 
to iv phenytoin. Black bars represent scenarios where increasing the value of the parameter leads to iv levetiracetam being dominant compared to iv phenytoin.
Abbreviations: ADR, adverse drug reaction; iCU, intensive care unit.
group (87.5%) versus the iv phenytoin group (75.9%), an 
absolute difference of 11.6% favoring iv levetiracetam.
A tornado diagram illustrates the impact of each model 
parameter on the incremental cost difference between iv 
levetiracetam and iv phenytoin (Figure 2). Decreasing the 
cost of a vial of levetiracetam 500 mg and the probability 
of seizures with iv levetiracetam had the most impact on 
the base-case results. Sensitivity was observed in 8 of the 
parameters used in the DA model. In several cases, iv leve-
tiracetam was a dominant strategy compared to iv phenytoin. 
Increasing phenytoin’s probability of ADR, vial cost, and 
seizure probability resulted in iv levetiracetam being domi-
nant. Increasing the number of days that an ADR results in 
an increase in ICU stay and ICU bed stay cost resulted in ClinicoEconomics and Outcomes Research 2010:2 20
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iv levetiracetam being dominant. Decreasing the number of 
days in the ICU as a consequence of a seizure event resulted 
in iv levetiracetam being dominant.
In the probabilistic sensitivity analysis, a majority of the 
trial simulations were displayed in the northeast (trade-off) 
quadrant (56.11%) with a small sample of the trial simula-
tions in the northwest (dominated) quadrant (1.66%); but 
42.33% of the scatter plots were displayed in the dominant 
quadrant (southeast quadrant) (Figure 3). Simulations fall-
ing in the northeast quadrant were considered a “trade-off” 
because the treatment (iv levetiracetam) was more expensive 
but more effective than the comparator (iv phenytoin).31 
Simulations falling in the northwest quadrant were consid-
ered dominated because the treatment (iv levetiracetam) was 
less effective and but more costly than the comparator (iv 
phenytoin).31 Simulations falling into the southwest quad-
rant were considered a “trade-off” because the treatment 
(iv levetiracetam) was less expensive but less effective than 
the comparator (iv phenytoin). Simulations falling in the 
southeast quadrant were considered dominant because the 
treatment (iv levetiracetam) was less costly and more effec-
tive than the comparator (iv phenytoin).31
A CEAC is a common and useful way to graphically 
represent uncertainty in economic analyses of healthcare 
technologies.29,30 It represents the probability that a given 
treatment will be cost-effective when compared to an 
alternative at different thresholds of what decision makers are 
willing to pay for a given outcome.29,30 For example, if the WTP 
was defined as $15,000 for each additional SSPR gained, then 
iv levetiracetam is 95% cost-effective compared to iv phenytoin 
(Figure 4). The CEAC illustrates that iv levetiracetam was cost-
effective at a WTP greater than $360.82 per additional SSPR 
gained compared to iv phenytoin. Conversely, iv phenytoin 
would be cost-effective at a WTP less than $360.82 per addi-
tional SSPR gained compared to iv levetiracetam.
Discussion
The results of our analysis suggest that levetiracetam may 
be a cost-effective early onset seizure prophylaxis strategy 
after neurosurgery or TBI when the WTP is greater than 
$360.82 per additional SSPR gained. There is no commonly 
accepted treatment algorithm for early seizure prophylaxis 
after neurosurgery or TBI; however, phenytoin has the most 
evidence and is commonly used in most institutions including 
our own local facility.12 However, iv phenytoin has several 
limitations, including drug level monitoring, liver enzyme 
elevation, rare but serious skin reactions, and significant drug 
interactions.14,15 This has led to an interest in using newer 
AEDs for this indication, such as iv levetiracetam, which do 
not have the aforementioned problems.
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The average cost-effectiveness ratio of levetiracetam 
was approximately 7% lower than that of phenytoin, with an 
ICER of $360.82 per SSPR gained. The additional resources 
spent on iv levetiracetam are partially offset by decreases in 
other costly healthcare resources such as length of ICU bed 
stay and laboratory monitoring. In our study, length of stay 
(which was influenced by seizure prophylaxis drug choice) 
was the primary cost driver. Decision maker’s consideration 
for this early seizure prophylaxis in neurosurgery patients 
will need to be determined by the institution and based on 
their WTP. Clearly, the reduction in LOS and improvement in 
seizure prevention are advantages to using iv levetiracetam; 
however, it was not a dominant strategy in our analysis and 
would require additional budget or reallocation of funds in 
order to realize these benefits.
The model was not robust to the sensitivity analyses as 
evident by the tornado diagram. Eight of the 12 parameters 
that underwent one-way sensitivity analyses were sensitive 
across the range used. These examples demonstrate that iv 
levetiracetam dominance is dependent on slight changes to 
the model parameters. Each institution may have a different 
patient population that is not reflected by the base-case; as 
a result, any deviations from the DA model parameters can 
result in iv levetiracetam being a dominant strategy. Careful 
interpretation of the study is necessary when applying the 
results to different institutions.
Our sensitivity analysis showed that laboratory costs 
associated with phenytoin was non-contributory. However, 
this analysis did not capture indirect costs such as staffing 
resource allocation needed for phenytoin monitoring. The 
drawing and monitoring of these labs can consume various 
healthcare workers’ time, including clinical pharmacists, 
nurses, physicians, and laboratory workers. Freeing hospital 
employees from this burden could free them for other patient 
care activities and potentially improve work flow. In our 
analysis, the decision to not include these additional costs 
most likely underestimated the overall costs of iv phenytoin. 
Future studies should evaluate the influence of indirect costs 
to overall decision making.
There are several limitations to our analysis. First, the 
clinical data used for model probabilities was taken from 
a heterogenic collection of studies that were prospective,23 
retrospective,21 and pseudo-prospective22 studies, and evalu-
ated patients who underwent neurosurgery21 or had neurologic 
damage.22,23 The results may not necessarily be generalizable 
to indications such as different types of neurosurgery and 
traumatic brain injuries. Larger studies dedicated to each 
indication will be necessary to clarify if there are differences 
in seizure control. Second, the outcome parameter used in 
the DA model (eg, SSPR) is unique and does not have an 
explicit cost-effectiveness threshold associated with it. This 
makes it difficult to determine the cost-effectiveness across 
different disease states. Standardized outcomes such as 
quality-adjusted life years (QALYs) are able to transcend 
different disease states and provide decision makers with 
a common parameter to compare treatment interventions.27 
However, the short duration of the current study makes the 
usefulness of QALY as an outcome uncertain. Third, this 
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study only applies to early onset seizure prophylaxis within 
one week of neurosurgery or neurologic damage, and cannot 
be extrapolated beyond this short term time frame. Seizure 
events outside the time frame (ie, late seizures) may be 
associated with the efficacy of the treatment intervention; 
however, there may be other confounding variables that can 
affect this outcome.13 Decision makers should use caution 
when generalizing these results to their institutions.
The role that early seizures play in development of late 
seizures is not clear. After TBI, patients with early seizures 
have a 17% to 33% chance of developing late epilepsy, 
compared to just 2% of all TBI patients.32 Multivariate 
analyses on this topic have had mixed results. One pooled 
analysis of 783 high risk trauma patients followed for 
2 years via a clinical trial found early seizures to be an 
independent risk factor for epilepsy.6 However, another 
population based cohort that followed 4541 adults and 
children for 20 years after head injury did not find early 
seizures to be correlated with development of epilepsy.33 
More evidence is needed to determine if a relationship 
between early and late seizure exists. In addition, it is 
unclear if utilization of newer AEDs for early prophylaxis 
results in an increase use for late prophylaxis which may 
affect long term costs. Such an impact is unclear and was 
not assessed in this study. However, switching patients to 
more cost-effective agents in a stable outpatient setting 
seems feasible. Clinical practice on this matter will likely 
vary widely between institutions.
In our analysis, iv levetiracetam was more cost-effective 
compared to iv phenytoin for early onset seizure prophylaxis 
after neurosurgery or neurologic damage. There is an interest 
in using the newer AEDs (eg, iv levetiracetam) for seizure 
prophylaxis in neurosurgery patients due to concerns with 
constant laboratory monitoring, unpredictable drug concen-
tration with older agents (eg, phenytoin), and ADRs. Some 
institutions have switched to newer agents like levetiracetam 
for early onset seizure prophylaxis, but practice still varies 
from institution to institution. Moreover, there is no clear 
consensus on which prophylactic regimen should be used at 
this time and some institutions may use agents which were 
not assessed in this analysis.
Future prospective clinical studies are needed to provide 
more complete evidence to support use of the newer AEDs 
in this indication. Future pharmacoeconomic analyses should 
take advantage of new clinical data when it becomes available 
and reevaluate the cost-effectiveness analysis of iv leveti-
racetam versus iv phenytoin in early seizure prophylaxis in 
postoperative neurosurgical or TBI patients.
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